China300401.CS▼
Huayuan Bio's 2026 interim net profit was 132 million yuan, down 18.34% year-on-year
Huayuan Bio released its 2026 interim report, with net profit attributable to the parent company of 132 million yuan, down 18.34% from the same period last year. The company's total operating revenue was 692 million yuan, up 8.93% year-on-year, achieving growth for two consecutive years. Net cash inflow from operating activities was 195 million yuan, down 29.16% year-on-year. The company's latest gross margin was 45.25%, down 10.69 percentage points from the same period last year, and its latest ROE was 3.69%, down 1.14 percentage points year-on-year. Diluted earnings per share were 0.24 yuan, down 20.00% year-on-year.